Why Biobank? A recent article was published explaining why there are many names scientists often suggest as an alternative to the word “biobank.” In his article, Biobanks: Why All the Names, Robert Hewitt wrote that biobanks are not meeting the expectations of patients, researchers and the society as a whole1.
Reasons for Dr. Hewitt’s perception are indicated as such. Retrospectively collected biospecimens, which exist in most biobanks, may not meet the requirements of the studies of the researchers. Additionally, the consent forms patients sign for the use of their biospecimens may not cover the proposed research. Finally, a highly selective review process can delay the release of biospecimens from the biobank.
A different author, Dominic Allen, once wrote biobanks should collect biospecimens prospectively in a trusted collection of networks2 to overcome some of these limitations. Fortunately, the Cooperative Human Tissue Network’s (CHTN) founders had the foresight... Read more
June 23, 2017 at 10AM EDTSponsored by the NIH Data Science Special Interest GroupNational Library of Medicine
The NIH Data Science Special Interest Group is proud to host the webinar Global Perspective on Biobanking and Access to Samples on Friday June 23, 2017 at 10 am EDT. Biobanking leaders from around the world will discuss the challenges and obstacles in sharing and accessing samples and their associated data. The discussion will also address samples that are scarce and how to overcome challenges associated with obtaining these samples. The online audience will be able to send questions directly to the panelists through the GoToWebinar interface. We hope the webinar will facilitate further discussion on these issues and generate new ideas for possible solution and collaboration.Panelists include:
Jonathan Pevsner, Professor, at the Dept. of Neurology, Kennedy Krieger Institute, Dept. of Psychiatry and Behavioral Sciences, Johns Hopkins Medicine. Presentation:... Read more